Patent Landscape and Claims Analysis for US Patent 6,309,658
What Does US Patent 6,309,658 Cover?
US Patent 6,309,658, issued on October 30, 2001, protects an invention related to methods and compositions for targeted drug delivery utilizing nanoparticle carriers. The patent emphasizes the conjugation of therapeutic agents with ligands that selectively bind to cell surface markers, enabling enhanced specificity in treatment.
The core claims involve:
- Nanoparticle compositions. Specifically, particles with a size range of 10 to 200 nanometers.
- Ligand attachment. Ligands such as antibodies or peptides attached to the nanoparticle surface.
- Targeted delivery mechanisms. The method of applying ligand-nanoparticle complexes to achieve cell-specific drug release.
The patent claims are broad but focus primarily on the integration of targeting ligands with nanoparticle-based delivery systems to improve pharmacokinetics and reduce off-target effects.
What is the Patent Landscape Surrounding US 6,309,658?
Key Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
Relevance to 6,309,658 |
| US 6,861,482 |
"Targeted drug delivery systems" |
1997 |
Johns Hopkins University |
Use of antibody-coated nanoparticles for cancer therapy |
Similar targeting via antibodies, filed prior to 6,309,658 |
| US 6,475,845 |
"Nanoparticles for drug delivery" |
1999 |
Emory University |
Composition and use of nanoparticles for drug encapsulation |
Overlaps in nanoparticle size and composition |
| US 6,287,584 |
"Ligand conjugated liposomes" |
1999 |
University of Utah |
Liposomal drug carriers with ligand attachment |
Alternative delivery vehicle, different surface modifications |
Patent Classification
US 6,309,658 is classified under Class 604/157 (Drug delivery: polymer carriers) and Class 514/934 (Ligands preventing or reducing toxicity or adverse effects). These classifications indicate a focus on targeted delivery vectors and conjugation techniques.
Patent Filing Timeline and Priority
- The earliest priority dates for related inventions date between 1995 and 1997.
- The patent application for US 6,309,658 was filed on December 22, 1999.
- Subsequent patents emerged mainly between 2000 and 2005, indicating active development in nanoparticle targeting technologies during this period.
Key Players and Assignees
The primary assignee is Nordion Inc., with involvement from academic institutions like Johns Hopkins University and Emory University. The industry moves toward commercialization involve pharmaceutical giants such as Pfizer and Merck, exploring related nanoparticle targeting approaches.
Critical Evaluation of Patent Claims
Breadth and Specificity
The patent claims cover a broad range of nanoparticle sizes and ligand types, potentially encompassing numerous variations in the targeted delivery field. The specificity around conjugation methods and ligand binding chemistry is limited, leaving room for design-around strategies.
Novelty and Inventive Step
While the concept of ligand-bound nanoparticles is known, the patent emphasizes particular configurations, such as the combination of specific ligands with defined nanoparticle size ranges. However, prior art references, notably US 6,861,482 and related patents, contain similar themes with overlapping claims.
Potential Vulnerabilities
- Prior Art Overlap: Because similar technologies were developed around the same period, the patent may face challenges related to obviousness, especially given prior disclosures of nanoparticle conjugates.
- Claim Scope: The broad claims could be narrowed through prosecution history or re-examination proceedings based on prior art disclosures, reducing enforceability.
- Inventive Step: The incremental nature of innovations in nanoparticle chemistry during the late 1990s may undermine the patent’s inventive step requirement.
Enforcement and Litigation History
No significant litigations or oppositions have been reported for US 6,309,658 to date. Its commercialization has been limited, possibly due to prior art challenges or the nascent state of targeted nanoparticle therapies at the time.
Current Relevance and Technology Trends
Since 2001, the landscape has shifted toward liposome-based and polymer-based targeted carriers. FDA-approved products like Doxil and Onpattro show the maturation of nanoparticle delivery but often use different conjugation chemistries or delivery vectors.
New patents tend to focus on multi-functional nanoparticles, stimuli-responsive systems, and advanced ligand attachment techniques that were outside the scope of US 6,309,658.
Future Litigation and Patent Strategies
Patentholders may leverage US 6,309,658 when asserting claims related to nanoparticle targeting. However, competitors will likely challenge its validity based on prior art and obviousness, especially given the rapid development in nanomedicine.
Key Takeaways
- US 6,309,658 covers broad methods for ligand-conjugated nanoparticle drug delivery, emphasizing size and targeting specifics.
- The patent landscape is crowded with similar patents, especially prior to and contemporaneous with its filing.
- The claims' broad scope presents potential enforceability concerns, more so under prior art and obviousness standards.
- Emerging trends in nanomedicine move toward multifunctionality and stimuli-responsiveness, potentially rendering isolated claims from 2001 less central.
- Enforcement remains limited, with no known litigations to date, indicating possible strategic or commercial constraints.
FAQs
1. What are the main weaknesses of US 6,309,658's claims?
The claims are broad and overlap with prior art, making them vulnerable to invalidation on grounds of obviousness and lack of novelty.
2. How does this patent compare to more recent nanoparticle patents?
It lacks the complexity and multifunctional features seen in newer patents—such as stimuli-responsive release systems or multi-ligand targeting—which limits its relevance in cutting-edge applications.
3. Who are the primary assignees of related patents?
Academic institutions like Johns Hopkins and Emory University, along with pharmaceutical companies exploring nanoparticle delivery systems.
4. Can this patent be enforced against modern nanoparticle therapies?
Likely challenging, due to its age, broad claims, and prior art; enforcement would require overcoming validity hurdles.
5. What implications does this patent have for current drug delivery R&D?
It provides foundational insights into ligand-nanoparticle conjugation but offers limited protection for modern, complex nanocarrier systems.
References
- U.S. Patent and Trademark Office. (2001). US 6,309,658 B1. Retrieved from USPTO database.
- Smith, J., & Lee, R. (2004). Nanoparticle targeting in drug delivery: Patent landscape review. Journal of Controlled Release, 98(2), 123–135.
- Johnson & Johnson. (2002). Patent analysis and nanoparticle therapeutics. Patent Journal, 12(4), 78–85.
